Novo Nordisk to begin 2024 share buybacks
OSLO (Reuters) – Novo Nordisk will on Tuesday begin the execution of its planned share buyback programme for 2024, the Danish maker of obesity drug Wegovy and diabetes treatment Ozempic said in a statement.
Novo on Jan. 31 said it planned to carry out a share repurchase plan of up to 20 billion Danish crowns ($2.88 billion) to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes.
The company completed its previous 12-month share repurchase programme on Jan. 30.
($1 = 6.9337 Danish crowns)
(Reporting by Terje Solsvik, editing by Anna Ringstrom and Essi Lehto)
Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.